SIL204 treatment may help immune system attack KRAS-driven tumors, research finds - exclusive
This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center
Assessment
SIL204, a treatment that may enable the immune system to attack KRAS-driven tumors, has advanced to Phase 2/3 clinical evaluation. The first trial is underway at Tel Aviv Sourasky Medical Center. This development signals a potential new therapeutic avenue for cancers driven by KRAS mutations, which have historically been difficult to target.